178 related articles for article (PubMed ID: 31634188)
21. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
24. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
25. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
[TBL] [Abstract][Full Text] [Related]
26. Comparing a point-of-care urine tenofovir lateral flow assay to self-reported adherence and their associations with viral load suppression among adults on antiretroviral therapy.
Phillips T; Gomba Y; Myer L
Trop Med Int Health; 2024 Feb; 29(2):96-103. PubMed ID: 38084797
[TBL] [Abstract][Full Text] [Related]
27. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
28. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Robles G; Sauermilch D; Gandhi M; Starks TJ
AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
[TBL] [Abstract][Full Text] [Related]
29. A competitive lateral flow assay for the detection of tenofovir.
Pratt GW; Fan A; Melakeberhan B; Klapperich CM
Anal Chim Acta; 2018 Aug; 1017():34-40. PubMed ID: 29534793
[TBL] [Abstract][Full Text] [Related]
30. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
[TBL] [Abstract][Full Text] [Related]
31. Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
McCluskey SM; Govender K; Adamson J; Gandhi M; Spinelli MA; Moosa MY; Muyindike W; Moodley P; Pillay M; Masette G; Sunpath H; Pillay S; Chen G; Hedt-Gauthier B; Marconi VC; Siedner MJ
AIDS; 2023 Jun; 37(7):1109-1113. PubMed ID: 36928169
[TBL] [Abstract][Full Text] [Related]
32. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
33. Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria.
Adeyemi OA; Nowak RG; Marzinke M; Morgan D; Sam-Agudu N; Craddock J; Zhan M; Crowell TA; Baral S; Ndembi N; Adebajo S; Charurat ME;
PLoS One; 2023; 18(3):e0282999. PubMed ID: 36928630
[TBL] [Abstract][Full Text] [Related]
34. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
35. Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin.
Mboup A; Béhanzin L; Guédou F; Giguère K; Geraldo N; Zannou DM; Kêkê RK; Bachabi M; Gangbo F; Affolabi D; Marzinke MA; Hendrix C; Diabaté S; Alary M
Medicine (Baltimore); 2020 May; 99(21):e20063. PubMed ID: 32481273
[TBL] [Abstract][Full Text] [Related]
36. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
[TBL] [Abstract][Full Text] [Related]
37. A case study of chewed Truvada
Lalley-Chareczko L; Clark D; Zuppa AF; Moorthy G; Conyngham C; Mounzer K; Koenig H
Antivir Ther; 2017; 22(7):639-641. PubMed ID: 28260694
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
Agot K; Taylor D; Corneli AL; Wang M; Ambia J; Kashuba AD; Parker C; Lemons A; Malahleha M; Lombaard J; Van Damme L
AIDS Behav; 2015 May; 19(5):743-51. PubMed ID: 25100053
[TBL] [Abstract][Full Text] [Related]
39. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies with subnanomolar affinity to tenofovir for monitoring adherence to antiretroviral therapies: from hapten synthesis to prototype development.
Cavalera S; Agulló C; Mercader JV; Di Nardo F; Chiarello M; Anfossi L; Baggiani C; D'Avolio A; Abad-Somovilla A; Abad-Fuentes A
J Mater Chem B; 2020 Dec; 8(45):10439-10449. PubMed ID: 33124633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
